Aaron Kesselheim weighs in on niche drugs.

Drug companies’ investor-driven business model allows them to make risky research bets to develop innovative drugs. But at the end of the day, it means products that are essential to sick people are being made by businesses.

What Gene-Altering for Pigs Might Mean for Humans by Amy Dockser Marcus

In new studies that demonstrate how quickly genetics science is advancing, researchers used the Crispr gene-editing system to make long-sought alterations in animals, with potential relevance for human health.

Robert Truog, director of the Harvard Medical School Center for Bioethics

The announcement by Oregon Health & Science University that scientists there had edited the genes of human embryos to remove the cause of a

Ethical issues in Charlie Gard case.

Center for Bioethics Director Robert Truog authored this Viewpoint article in the Journal of the American Medical Association.

Center for Bioethics faculty member J. Wesley Boyd coauthored this piece about the critical shortage of child phyciatrists in the United States.

Autumn Fiester, PhD, will be a plenary speaker for the 2017 Harvard Clinical Bioethics Course. During the course Fiester will discuss conflict management for challenging ethics consultations.

Crowdfunding Medical Care: Identifying ethical implications
Wednesday, April 5
12:30 pm
Register online here

In every trial there is a balance between the risks and benefits to study participants, and the principles of research ethics require that the likely benefits of participation outweigh the risks.

The Annual Bioethics Conference at Harvard Medical School is a two day, single track conference that facilitates conversations among experts about emerging ethical issues.